Skip to main content
PLEASE NOTE: For everyone’s safety, Fasken requires anyone on-site at our Canadian offices to provide proof of full vaccination against COVID-19. This applies to lawyers, staff, clients, service providers and other visitors.
Client Work

Global drug manufacturer launches first major subsequent entry biologic following Health Canada approval

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Confidential Client

Timothy Squire of Fasken Martineau advised a global drug manufacturer in the launch of the first major subsequent entry biologic (SEB) following Health Canada approval.

Team

    Subscribe

    Receive email updates from our team

    Subscribe